Richard S. Foster

Richard S. Foster's AcademicInfluence.com Rankings

Richard S. Foster

Philosophy

#9853

World Rank

#13469

Historical Rank

Logic

#6810

World Rank

#8360

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Richard S. Foster Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard S. Foster's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. (1999) (291)
Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. (1990) (275)
Noninvasive surgery of prostate tissue by high-intensity focused ultrasound (1996) (265)
Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. (1993) (255)
Late relapse of testicular cancer. (1995) (237)
Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. (2001) (202)
Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. (2001) (194)
Complications of post-chemotherapy retroperitoneal lymph node dissection. (1995) (177)
Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. (1993) (176)
Update on late relapse of germ cell tumor: a clinical and molecular analysis. (2003) (168)
Complications of primary retroperitoneal lymph node dissection. (1994) (165)
Original Articles: Testis Cancer: Complications of Post-Chemotherapy Retroperitoneal Lymph Node Dissection (1995) (158)
Use of ileum as ureteral replacement in urological reconstruction. (2009) (157)
The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). (1995) (153)
High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. (1994) (137)
Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? (2010) (137)
High-intensity focused ultrasound in the treatment of prostatic disease. (1993) (131)
The pathology of late recurrence of testicular germ cell tumors. (2000) (130)
Active surveillance is the preferred approach to clinical stage I testicular cancer. (2013) (123)
Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. (1994) (121)
Complications of retroperitoneal lymph node dissection. (1981) (112)
Integration of surgery and systemic therapy: results and principles of integration. (1998) (109)
Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? (2007) (108)
Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. (2000) (108)
Legionnaires' disease in patients with associated serious disease. (1979) (108)
Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? (2003) (106)
Primitive neuroectodermal tumors arising in testicular germ cell neoplasms. (1997) (104)
Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. (2004) (103)
Molecular genetic alterations in the laser‐capture–microdissected stroma adjacent to bladder carcinoma (2003) (100)
Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. (1995) (99)
Ultrasound and microbubbles: their generation, detection and potential utilization in tissue and organ therapy--experimental. (1995) (97)
The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. (2005) (94)
Management of chylous ascites after retroperitoneal lymph node dissection for testicular cancer. (1993) (94)
Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. (2000) (91)
Adult primary pure teratoma of the testis. The Indiana experience (1995) (90)
Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. (1995) (88)
Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. (1996) (87)
Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. (2005) (87)
Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. (1998) (80)
Preoperative technetium Tc 99m sestamibi imaging. Paving the way to minimal-access parathyroid surgery. (1996) (80)
Does retroperitoneal lymph node dissection have a curative role for patients with sex cord–stromal testicular tumors? (2003) (78)
Late relapse of clinical stage I testicular cancer. (1995) (77)
Surgical anatomy of the lumbar vessels: implications for retroperitoneal surgery. (1995) (75)
Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. (2007) (75)
Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. (2003) (75)
Morbidity and mortality after thyroidectomy. (1978) (74)
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. (2015) (72)
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium (1999) (69)
Interphase Fluorescence In situ Hybridization Analysis of Chromosome 12p Abnormalities Is Useful for Distinguishing Epidermoid Cysts of the Testis from Pure Mature Teratoma (2006) (66)
OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. (2006) (66)
Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes. (2014) (65)
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors (2018) (64)
Fine needle aspiration of the breast. Importance of the aspirator. (1987) (60)
Hepatic Resection of Metastatic Testicular Carcinoma: A Further Update (1999) (59)
Early catheter removal after radical retropubic prostatectomy: long-term followup. (2003) (59)
Teratoma in the Orchiectomy Specimen and Volume of Metastasis are Predictors of Retroperitoneal Teratoma in Post-Chemotherapy Nonseminomatous Testis Cancer (1996) (59)
Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. (2001) (59)
Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? (2014) (59)
Nephroblastoma Arising in a Germ Cell Tumor of Testicular Origin (2004) (58)
Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements (2010) (58)
Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. (1998) (58)
Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy. (1994) (57)
Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis (2004) (56)
Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. (2014) (56)
Germ cell tumor associated primitive neuroectodermal tumors. (2001) (55)
Breast cancer and pregnancy. (2000) (55)
Feasibility of omitting cortical renorrhaphy during robot-assisted partial nephrectomy: a matched analysis. (2015) (55)
Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. (2000) (55)
High-intensity focused ultrasound in the treatment of prostatic tissue. (1994) (54)
“Somatic-type” Malignancies Arising From Testicular Germ Cell Tumors: A Clinicopathologic Study of 124 Cases With Emphasis on Glandular Tumors Supporting Frequent Yolk Sac Tumor Origin (2014) (53)
The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. (1996) (53)
Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. (2003) (52)
Bilateral testicular tumors (1998) (52)
The fertility of patients with clinical stage I testis cancer managed by nerve sparing retroperitoneal lymph node dissection. (1994) (52)
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157 (2016) (51)
Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. (2010) (51)
Production of prostatic lesions in canines using transrectally administered high-intensity focused ultrasound. (1993) (50)
Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. (2010) (50)
Breast cancer and aging. (1989) (50)
Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder (2010) (50)
En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. (1998) (49)
Is retroperitoneal lymph node dissection necessary for adult paratesticular rhabdomyosarcoma? (1998) (49)
Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. (2000) (49)
Molecular Genetic Evidence Supporting the Origin of Somatic-type Malignancy and Teratoma From the Same Progenitor Cell (2012) (48)
Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. (1998) (48)
Anatomic distribution of periprostatic adipose tissue (2003) (48)
Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. (1996) (47)
Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. (2001) (45)
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. (2017) (45)
Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications. (2015) (44)
Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients. (2007) (44)
Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. (2002) (43)
Histology in mixed germ cell tumors. Is there a favorite pairing? (2004) (43)
Clinical stage I nonseminoma: surgery versus surveillance. (1998) (42)
Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. (1998) (42)
Cystography after radical retropubic prostatectomy: clinical implications of abnormal findings. (1995) (41)
Cystic Trophoblastic Tumor: A Nonaggressive Lesion in Postchemotherapy Resections of Patients With Testicular Germ Cell Tumors (2004) (41)
Clonal Origin of Metastatic Testicular Teratomas (2006) (41)
Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. (2006) (41)
Nerve-sparing retroperitoneal lymphadenectomy. (1990) (40)
Serum tumor markers in testicular cancer. (2013) (40)
Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. (2019) (39)
Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. (1996) (39)
Nephroblastoma-like tumors in patients with testicular germ cell tumors. (1998) (38)
Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. (1994) (38)
Early urethral catheter removal following radical prostatectomy: a pilot study. (1995) (38)
Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. (2000) (37)
Detection of antisperm-antibodies in patients with primary testicular cancer. (1991) (37)
Resection of the inferior vena cava or intraluminal vena caval tumor thrombectomy during retroperitoneal lymph node dissection for metastatic germ cell cancer: indications and results. (1991) (37)
Early clinical experience with the transverse colon-gastric tube continent urinary reservoir. (1991) (37)
Noninvasive ultrasonic subtotal ablation of the prostate in dogs. (1996) (37)
The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. (1995) (36)
Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? (1998) (35)
The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis. (1994) (35)
Modified retroperitoneal lymph node dissection for post‐chemotherapy residual tumour: a long‐term update (2017) (34)
Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage a nonseminomatous testicular germ cell tumor at low risk for occult metastasis (1995) (34)
GROWING TERATOMA SYNDROME AFTER CHEMOTHERAPY FOR GERM CELL TUMORS OF THE OVARY (1994) (33)
Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen? (2006) (33)
Legionnaires' disease in renal transplant patients. (1981) (33)
Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. (2005) (33)
Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors (1994) (32)
Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors. (1995) (32)
Urethral catheter removal prior to hospital discharge following radical prostatectomy. (1997) (32)
Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors (1995) (31)
Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? (2006) (30)
Unusual neoplasms detected in testicular cancer patients undergoing postchemotherapy retroperitoneal lymphadenectomy (1994) (29)
Color Doppler flow imaging for deep venous thrombosis screening in patients undergoing pelvic lymphadenectomy and radical retropubic prostatectomy for prostatic carcinoma. (1995) (29)
Flow‐cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical‐stage‐I non‐seminomatous testicular germ‐cell tumors (1994) (28)
Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer (2006) (27)
Identification of multiple chromosome 12 abnormalities in human testicular germ cell tumors by two‐color fluorescence in situ hybridization (FISH) (1995) (26)
Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma (2009) (26)
Use of a caval-atrial shunt for resection of a caval tumor thrombus in renal cell carcinoma. (1988) (25)
Chyloperitoneum following treatment for advanced gynecologic malignancies (1994) (24)
Molecular genetic evidence supporting the neoplastic nature of fibrous stroma in testicular teratoma (2012) (24)
Ectopic ureters and ureteroceles in adults. (1995) (24)
The impact of pre-donated autologous blood and intra-operative isovolaemic haemodilution on the outcome of transfusion in patients undergoing radical retropubic prostatectomy. (1996) (23)
Management of retroperitoneal recurrences. Seminoma and nonseminoma. (1994) (23)
Spinal cord ischemia after post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell cancer. (1996) (22)
Impact of the number of positive lymph nodes on disease-free survival in patients with pathological stage B1 nonseminomatous germ cell tumor. (2005) (22)
Role of serum prolactin determination in evaluation of impotent patient. (1990) (21)
Biochemical disease‐free survival in patients with a high prostate‐specific antigen level (20–100 ng/mL) and clinically localized prostate cancer after radical prostatectomy (2003) (21)
Molecular evidence supporting the neoplastic nature of some epidermoid cysts of the testis. (2003) (21)
Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. (2007) (21)
Risk for Clostridium difficile infection after radical cystectomy for bladder cancer: Analysis of a contemporary series. (2015) (21)
Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. (1996) (20)
Salmonella enteritidis: testicular abscess in a newborn. (1983) (20)
Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. (2003) (20)
Fluorescence in situ hybridization on nuclei from paraffin-embedded tissue in low stage pure embryonal carcinoma of the testis. (1998) (20)
Retroperitoneal lymph node dissection in testicular cancer. (2007) (19)
Bilateral testicular epidermoid cysts managed by partial orchiectomy. (2002) (19)
Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. (2012) (19)
Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. (2017) (19)
The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. (2015) (19)
Splenic rupture during occlusion of the porta hepatis in resection of tumors with vena caval extension. (1994) (18)
Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy? (2005) (18)
Outcomes of postchemotherapy retroperitoneal lymph node dissection following high‐dose chemotherapy with stem cell transplantation (2015) (18)
Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome. (2007) (18)
Percutaneous access to a continent urinary reservoir for removal of intravesical calculi: a case report. (1993) (18)
Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. (2001) (18)
Stage I nonseminomatous germ-cell testicular cancer — management options and risk-benefit considerations (1994) (17)
Update on the Indiana Continent Urinary Reservoir (1991) (17)
Current status of retroperitoneal lymph node dissection and testicular cancer: when to operate. (2002) (16)
Creation of a transverse colon--gastric composite reservoir: a new technique. (1989) (16)
Prevention of post-prostatectomy vesical neck contracture by prophylactic vesical neck incision. (1987) (16)
Microbubbles during tissue treatment using high intensity focused ultrasound (1995) (16)
High-intensity focused ultrasound (1995) (16)
Selective renal arteriography in medical diseases of the kidney. (1965) (16)
Preoperative Nomograms for Predicting Renal Function at 1 Year After Partial Nephrectomy. (2017) (15)
Transverse colon-gastric tube composite reservoir. (1991) (15)
Clinical stage I pure yolk sac tumor of the testis in adults has different clinical behavior than juvenile yolk sac tumor. (2000) (15)
Testicular papillary cystadenomatous tumor of low malignant potential: a case report and discussion of the literature. (1988) (15)
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. (2016) (14)
Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival. (2014) (14)
Complications of Retroperitoneal Lymph Node Dissection. (2019) (14)
Conversion of an ileal conduit to a continent catheterizable stoma. (1992) (14)
Vesical endometriosis: medical or surgical treatment. (1987) (14)
Cytogenetic analyses of 85 testicular germ cell tumors: comparison of postchemotherapy and untreated tumors. (1999) (14)
Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection. (2014) (13)
Long‐Term Survival of Good‐Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution (2017) (13)
What is the appropriate follow-up after treatment? (1996) (13)
Vascular considerations in postchemotherapy (1994) (13)
Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors? (2005) (13)
Use of magnetic resonance imaging to determine surgical approach to renal cell carcinoma with vena caval extension. (1990) (12)
Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors. (2007) (12)
Retroperitoneal lymphadenectomy for clinical stage a testis cancer: Modifications of technique and impact on ejaculation (1994) (12)
A preliminary report: postoperative fertility assessment in nerve-sparing RPLND patients. (1993) (12)
Differentiated rhabdomyomatous tumors after chemotherapy for metastatic testicular germ-cell tumors: a clinicopathological study of seven cases mandating separation from rhabdomyosarcoma (2009) (12)
Management of patients with metastatic teratoma with malignant somatic transformation (2018) (12)
Differentiating reconstructive techniques in partial nephrectomy: a propensity score analysis. (2015) (12)
Complications of primary retroperitoneal lymph-node dissection for low-stage testicular cancer (2004) (12)
Surgical treatment of clinical stage A nonseminomatous testis cancer. (1992) (11)
Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. (2016) (11)
Testicular cancer: what's new in staging, prognosis, and therapy. (1999) (11)
Anastomotic suture granuloma following radical retropubic prostatectomy. (1990) (11)
Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors. (2018) (11)
The Evolution and Technique of Nerve-Sparing Retroperitoneal Lymphadenectomy. (2015) (11)
Early-stage testis cancer (2001) (11)
Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. (2013) (11)
Early catheter removal following radical retropubic prostatectomy. (2000) (10)
Evolving concepts in surgical management of testis cancer. (1992) (10)
High intensity focused ultrasound treatment of human BPH. (1994) (10)
Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection (2004) (10)
Division of prostatic anterior fibromuscular stroma reduces urethral resistance in an ex vivo human prostate model. (2010) (10)
A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. (2012) (10)
Stage A nonseminomatous testis carcinoma: rationale and results of nerve-sparing retroperitoneal lymphadenectomy. (1991) (10)
Hyperamylasemia after post-chemotherapy retroperitoneal lymph node dissection for testis cancer. (1995) (10)
Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors (2006) (10)
Vascular considerations in postchemotherapy (1994) (10)
Secondary surgery in germ cell tumors—when and how extensively should it be performed? (2004) (9)
Minimally invasive treatment of benign prostatic hyperplasia with high-intensity focused ultrasound using the Sonablate system: an updated report of Phase III clinical studies conducted in the USA (2002) (9)
EXPRESSION OF CYCLOOXYGENASE (COX) -1 AND COX-2 IN HUMAN INVASIVE TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER (1999) (9)
Post-chemotherapy resection of nonseminomatous germ cell testicular tumors metastatic to the mediastinum. (1996) (9)
Intra-abdominal desmoid tumor: an unusual case of recurrent tumor in a testis cancer patient. (1992) (9)
Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high‐grade prostate cancer (2009) (9)
What are the indications for postchemotherapy retroperitoneal lymph node dissection? (2014) (8)
Retroperitoneal fibrosis and nonmalignant ileal carcinoid. (1987) (8)
Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors. (2019) (8)
Adaptations of the Mitrofanoff principle in adult continent urinary reservoirs. (1995) (8)
Legionnaires' disease following renal transplantation. (1979) (8)
The changing reality of urothelial bladder cancer: should non‐squamous variant histology be managed as a distinct clinical entity? (2015) (8)
Percutaneous Imaging-Guided Access for the Treatment of Calculi in Continent Urinary Reservoirs (2002) (7)
Management of the post chemotherapy subcentimeter residual mass: the case for observation (2009) (7)
Transrectal ablation of prostate tissue using focused ultrasound (1993) (7)
Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy. (2019) (7)
Long-Term Toxicity of Radiation Therapy (2003) (7)
Critical analysis of the 2010 TNM classification in patients with lymph node-positive bladder cancer: influence of lymph node disease burden. (2014) (7)
430: Is Full Bilateral Retroperitoneal Lymph Node Dissection (RPLND) Always Necessary for Post Chemotherapy Residual Tumor? (2005) (7)
Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part II. (1994) (6)
Very late relapse of germ cell tumor as a teratoma: a case report and review of the literature (2014) (6)
Noninvasive ultrasound-produced volume lesion in prostate (1991) (6)
Ureteral stump transitional cell carcinoma in a patient with recurrent superficial bladder cancer: an argument for complete nephroureterectomy in selected patients. (1990) (6)
Testicular ultrasonography after chemotherapy for germ cell neoplasm: significance of highly hyperechoic lesions. (1992) (6)
Percutaneous transvesical drainage of a seminal vesicle abscess. (1998) (6)
Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part I--Vena cava. (1994) (6)
Surgical management of late relapse on surveillance in patients presenting with clinical stage I testicular cancer. (2014) (6)
Benign testicular tumor associated with Klinefelter's syndrome. (1994) (6)
Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum α‐fetoprotein (2009) (6)
Prognostic Effect of Carcinoma In Situ in Muscle‐invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy (2017) (6)
Defining new standards for adjuvant therapy of testis cancer. (1995) (5)
SELECTIVE RENAL ANGIOGRAPHY IN CLINICAL UROLOGY. (1963) (5)
High-intensity focused ultrasound for the treatment of benign prostatic hypertrophy. (1994) (5)
Modified retroperitoneal lymphadenectomy (2004) (5)
Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor. (2020) (5)
Current Medical Diagnosis and Treatment 1982 (1982) (5)
Flow cytometric and cytophotometric DNA analysis cannot predict subsequent tumour recurrence in pathological stage IIA/B non-seminomatous testicular germ cell tumour patients who do not receive adjuvant chemotherapy. (1995) (4)
LONGITUDINAL HEALTH RELATED QUALITY OF LIFE AFTER OPEN RADICAL CYSTECTOMY: COMPARISON OF ILEAL CONDUIT, INDIANA POUCH, AND ORTHOTOPIC NEOBLADDER. (2021) (4)
Local graft irradiation as an adjunct to pharmacologic immunosuppression. (1974) (4)
High-intensity focused ultrasound (HIFU) treatment of BPH: results of a multicenter phase III study (2003) (4)
Long-Term Toxicity of Chemotherapy (2003) (3)
Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings. (2008) (3)
Renal ischemia and contrast urography. (1977) (3)
Improving postoperative quality of care in germ cell tumor patients: Does scheduled alvimopan, acetaminophen, and gabapentin improve short-term clinical outcomes after retroperitoneal lymph node dissection? (2020) (3)
Three-tiered nodal classification system for bladder cancer: a new proposal. (2015) (3)
Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection. (2015) (3)
Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels. (2020) (3)
Traumatic dislocation of a testis. (1981) (3)
Management of Pelvic Metastases in Patients With Testicular Cancer. (2017) (3)
Seminar article Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer (2005) (3)
Testicular cancer: Increasing in incidence and curability (2000) (3)
Postchemotherapy retroperitoneal lymph node dissection for testis cancer (2011) (3)
Secondary tumors after initial successful treatment of metastatic testis cancer. (1999) (2)
Management of Duodenal Involvement During Retroperitoneal Lymph Node Dissection for Germ Cell Tumors. (2017) (2)
Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymphadenectomy for urologic cancers. (2019) (2)
Organ sparing surgery for malignant germ cell tumor of the testis: Editorial comment (2001) (2)
Laparoscopic Spermatic Vein Ligation in Dogs (1991) (2)
Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157. (2016) (2)
RESULTS OF RETROPERITONEAL LYMPH NODE DISSECTION IN CLINICAL STAGE I PURE YOLK SAC TUMOR IN ADULTS (1999) (2)
Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection (2004) (2)
Robotic and open partial nephrectomy for intermediate and high complexity tumors: a matched-pairs comparison of surgical outcomes at a single institution (2020) (2)
Biology of metastases and its clinical implications: testicular germ-cell tumors (2004) (2)
Reduction of azathioprine toxicity by hydrocortisone. (1977) (2)
591: Do Postchemotherapy Patients who Present with an Elevated Serum AFP and Pure Seminoma in the Orchiectomy Specimen Have a Higher Probability of Finding Necrosis only in the Retroperitoneal Lymph Node Dissection (RPLND) Specimen? (2006) (2)
Late relapse of germ cell tumors: Detection and treatment outcomes. (2021) (2)
Role of urologist in testis cancer management. (2011) (2)
Focal salmonella enteritidis infection of urinary tract. (1987) (2)
LONG TERM MORBIDITY AND SURVIVAL IN PATIENTS UNDERGOING VENA CAVA RESECTION FOR METASTATIC GERM CELL TUMORS (1999) (2)
Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors (2021) (2)
Reply to the letter to the editor 'A centralised multidisciplinary clinic approach for germ cell tumours' by Crawford. (2018) (1)
Construction of an antirefluxing urinary conduit using a plicated ileocecal segment. (1989) (1)
Role of routine stentograms following urinary diversion in modern practice. (2009) (1)
Prediction model for brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT) accounting for size of pulmonary metastases. (2021) (1)
970 PELVIC METASTASES AMONG PATIENTS UNDERGOING RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR CANCER (2011) (1)
Quantitative DNA measurement by flow cytometry and image analysis of human nonseminomatous germ cell testicular tumors (2004) (1)
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor. (2003) (1)
Presence of carcinoma in situ (CIS) in bladder cancer biopsies and its relationship to pathologic complete response (pCR) rates to neoadjuvant chemotherapy (neo-CTx). (2013) (1)
MP55-19 EFFICACY OF NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER (2014) (1)
Retroperitoneal lymph node dissection (2012) (1)
[Nerve sparing retroperitoneal lymphadenectomy (RLA)]. (2010) (1)
Chapter 38 – Radical Orchiectomy and Retroperitoneal Lymph Node Dissection (2005) (1)
High Pin1 expression is associated with tumor progression in colorectal cancer: Commentary (2006) (1)
A benign para-aortic lymph node of histologically proved follicular hyperplasia mimicking metastatic germ cell cancer. (2000) (1)
450: Extrapleural Retroperitoneal Approach for Isolated Retrocrural Metastatic Testis Cancer (2006) (1)
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor (2022) (1)
The updated indiana university experience with nerve sparing rplnd: effective organ preserving therapy (1997) (1)
The Role of Surgery in the Management of Recurrent or Persistent Non-seminomatous Germ Cell Tumors (2007) (1)
NONSEMINOMA GERM CELL TESTIS TUMOR MANAGED BY RETROPERITONEAL LYMPH NODE DISSECTION (2000) (1)
A pilot study to assess the accuracy of “intuition” in analyzing post chemotherapy (chemo) residual retroperitoneal (RP) masses in patients (pts) with non seminomatous germ cell tumor (NSCGCT). (2018) (1)
Management of Metastatic Pure Teratoma in Chemotherapy Naive Patients With Testicular Primaries (2020) (1)
RECURRENCE PATTERN IN PATIENTS WITH NECROSIS ONLY AT POST CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PCRPLND) (2008) (1)
Understanding the role of salvage lymphadenectomy in node only recurrences after nephrectomy for renal cell carcinoma. (2020) (1)
MP55-07 SIGNIFICANCE OF LYMPH NODE INVOLVEMENT IN VARIANT HISTOLOGY UROTHELIAL BLADDER CANCER (2014) (1)
Aggressive surgical management of germ cell tumors with somatic-type malignancy: Pathologic features, prognostic factors, and survival outcomes. (2013) (1)
Management of Late Relapse (2011) (0)
Adult UrologyOncology: Prostate/Testis/Penis/UrethraEditorial Comment (2006) (0)
Unrecognized Germ Cell Tumor Syndrome (2003) (0)
Management of pure metastatic teratoma in chemotherapy naïve testis cancer patients. (2017) (0)
PD5-05 SURGICAL MANAGEMENT OF RETROCRURAL DISEASE IN TESTIS CANCER: OUTCOMES AND EVOLUTION OF PRACTICE (2014) (0)
Editorial comment. (2010) (0)
Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only. (2023) (0)
711 MANAGEMENT OF MALIGNANT TRANSFORMATION DIAGNOSED EARLY IN THE TREATMENT OF GERM CELL TUMORS (2013) (0)
Management of Difficult Germ-Cell Tumors: Review 2 (2006) (0)
Therapy for Disseminated Disease (2003) (0)
Results a nd O utcome o f R etroperitoneal L ymph N ode Dissection f or C linical S tage I E mbryonal Carcinoma-Predom inant T estis C ancer (2000) (0)
PD03-02 UNDERSTANDING THE EFFECTIVENESS OF LYMPHADENECTOMY IN NODE ONLY RECURRENCES AFTER NEPHRECTOMY FOR KIDNEY CANCER (2019) (0)
Presence of variant histology (VarHst) in transurethral resection of bladder tumor (TURBT) biopsies and its prognostic significance on pathologic complete response (pCR) rates to neoadjuvant chemotherapy (neo-CTx). (2013) (0)
Treatment of Patients with “Poor-Risk” Disseminated Disease (2003) (0)
Aortic Replacement in Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Cancer (1994) (0)
586: What is the Short-Term Morbidity of Primary Retroperitoneal Lymph Node Dissection in a Contemporary Group of Patients? (2006) (0)
MP49-03 DOES SCHEDULED ALVIMOPAN, ACETAMINOPHEN AND GABAPENTIN IMPROVE SHORT-TERM CLINICAL OUTCOMES AFTER RETROPERITONEAL LYMPH NODE DISSECTION?: A PILOT STUDY (2019) (0)
Fertility in Nerve-Sparing RPLND (1994) (0)
BLEOMYCIN ASSOCIATED PULMONARY TOXICITY: IS PERIOPERATIVE OXYGEN RESTRICTION NECESSARY (1998) (0)
Commentary on "Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy." (2018) (0)
Reply by Authors. (2020) (0)
Detection of minimal tumor load in early stage nonseminomatous germ cell testicular tumors (NSGCT) (2007) (0)
Editorial Comment: Primary Chemotherapy in Patients with Nonseminomatous Germ Cell Tumors of the Testis and Biological Disease only after Orchiectomy (1996) (0)
IMPACT OF FERTILITY AFTER PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR PATIENTS WITH NON-SEMINOMATOUS GERM CELL TUMORS (NSGCT) (2009) (0)
Should laparoscopic RPLND replace open RPLND as the standard of care? No. The therapeutic value of laparoscopic RPLND is unproven (2006) (0)
MP10-17 MANAGEMENT OF CHYLOUS LEAK AFTER RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED TESTICULAR CANCER (2015) (0)
Surgery for Germ Cell Tumours: Current Status in the USA (2002) (0)
PD56-01 LONG-TERM ONCOLOGIC OUTCOMES AFTER PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION: MINIMIZING THE NEED FOR ADJUVANT CHEMOTHERAPY (2019) (0)
Stage II nonseminomatous germ-cell testicular tumors — the Indiana experience and risk-benefit analysis (1994) (0)
Adjuvant chemotherapy with CAV/IE for malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): An institutional analysis from Indiana University. (2021) (0)
[New parameters for prediction of pathological stage in clinical stage I non-seminomatous testicular tumors]. (1995) (0)
Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up (2004) (0)
Secondary retroperitoneal lymph node dissection in the management of recurrent germ cell testicular tumors (1997) (0)
Nerve-sparing post-chemotherapy rplnd (1997) (0)
AUTHOR REPLY. (2021) (0)
MP73-03 A HISTOLOGIC COMPARISON OF PATIENTS PRESENTING WITH PURE CHORIOCARCINOMA VS MIXED NSGCT WITH SERUM HCG LEVELS >20,000 IN PATIENTS UNDERGOING PC-RPLND (2019) (0)
Identification of novel immunomodulatory tumor biology through comprehensive characterization of a metastases-specific epigenome in patients with metachronous primary and metastatic urothelial carcinoma (UC) tumor pairs. (2016) (0)
Surgical Management of Retrocrural Disease in Germ Cell Tumors: Outcomes and Evolution of Practice. (2020) (0)
Complications of Retroperitoneal Lymphadenectomy (2007) (0)
833 PATHOLOGY AT POST CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PCRPLND) IN PATIENTS WITH CHORIOCARCINOMA SYNDROME OR PURE CHORIOCARCINOMA OF THE TESTIS (2011) (0)
Oncologic Emergencies (2007) (0)
Consolidation cystectomy after induction chemotherapy in node-positive urothelial bladder cancer. (2014) (0)
High-Dose Chemotherapy as Initial Salvage Therapy (2003) (0)
Is Radical Lymphadenectomy Indicated in Lymph Node-Positive Disease? (2003) (0)
Use of the Ileocecal Segment and Right Colon in Continent Diversion and Bladder Replacement (1995) (0)
Author Reply. (2017) (0)
Long-term Survival of Good Risk Germ Cell Tumor Patients following Post-chemotherapy Retroperitoneal Lymph Node Dissection: A comparison of BEPx3 vs. EPx4 and treating institution (2017) (0)
PD60-02 LONGITUDINAL HEALTH RELATED QUALITY OF LIFE AFTER RADICAL CYSTECTOMY (2020) (0)
Editorial comment. (2009) (0)
PD19-05 DOES PERCENTAGE OF SEMINOMA AT ORCHIECTOMY IMPACT PATIENT MORBIDITY AND PATHOLOGIC OUTCOMES AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR MIXED GERM CELL TUMOR? (2020) (0)
HISTOLOGIC FINDINGS OF LATE RELAPSED SEMINOMA MANAGED WITH RETROPERITONEAL LYMPH NODE DISSECTION: PD53‐06 (2017) (0)
2‐18FLUORO‐DEOXY‐D‐GLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG‐PET) IN SEMINOMA: IS AN OBJECTIVE SCORING SYSTEM USEFUL?: MP80‐09 (2017) (0)
Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? (2022) (0)
MP49-02 ONCOLOGIC OUTCOMES FOLLOWING SURGICAL MANAGEMENT OF CLINICAL STAGE II SEX CORD STROMAL TUMORS (2019) (0)
MP50-08 POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) FOR SEMINOMA: IS SURGERY EFFECTIVE? (2023) (0)
Urological Survey: Abstracts: Diagnostic Urology and Testis CancerPostchemotherapy Retroperitoneal Lymph Node Dissection is Effective Therapy in Selected Patients With Elevated Tumor Markers After Primary Chemotherapy Alone (1998) (0)
Neovascularization in clinical stage I testicular germ cell tumor as a predictor of metastatic disease (2007) (0)
Update o n L ate R elapse o f G erm C ell T umor: A C linical a nd Molecular A nalysis (2003) (0)
MP10-08 MODIFIED TEMPLATE RETROPERITONEAL LYMPH NODE DISSECTION FOR POSTCHEMOTHERAPY RESIDUAL TUMOR: A LONG TERM UPDATE (2015) (0)
Model to predict brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT). (2020) (0)
Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT). (2021) (0)
588 OUTCOMES OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOLLOWING HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT (2011) (0)
Treatment of Good-Risk Disseminated Germ Cell Tumors (2003) (0)
Non-seminomatous germ cell testis tumors (2012) (0)
Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward? (2023) (0)
Advances in Brief Expression of Cyclooxygenase-2 ( COX-2 ) in Human Invasive Transitional Cell Carcinoma ( TCC ) of the Urinary Bladder 1 (1999) (0)
2648 Novel DNA methylation therapeutic targets in urothelial carcinoma (UC) from patients with paired metachronous primary and metastatic tumors (2015) (0)
MP65-14 INCIDENCE AND RISK FOR CLOSTRIDIUM DIFFICILE INFECTIOUS COLITIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2015) (0)
Oncologic outcomes of primary retroperitoneal lymph node dissection (RPLND) for stage II seminoma: Indiana University experience. (2022) (0)
Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT). (2019) (0)
OP3-10 IMPACT OF BLEOMYCIN ON RETROPERITONEAL HISTOLOGY AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) IN GOOD RISK GERM CELL TUMORS (2014) (0)
PD34-07 DOES TERATOMA METASTASIZE? PRESENCE OF TERATOMA IN THE PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION SETTING (2016) (0)
Risk Factors for Relapse in Teratoma Resected Postchemotherapy for Metastatic Testis Cancer (1987) (0)
DOES THE DURATION OF SYMPTOMS BEFORE ORCHIECTOMY PREDICT METASTATIC DISEASE IN PATIENTS PRESENTING WITH CLINICAL STAGE A NONSEMINOMATOUS GERM CELL TUMOR (2008) (0)
665 LATE RECURRENCE IN PATIENTS WITH HISTORY OF COMPLETE REMISSION OF METASTATIC GERM CELL TUMORS TO CHEMOTHERAPY (2012) (0)
FLUORESCENCE IN SITU HYBRIDIZATION ON NUCLEI FROM CARCINOMA OF THE TESTIS PARAFFIN-EMBEDDED TISSUE IN LOW STAGE PURE EMBRYONAL (1998) (0)
PD19-02 OUTCOMES FOLLOWING RETROPERITONEAL LYMPH NODE DISSECTION FOR CLINICAL STAGE II PATIENTS EXPERIENCING A LATE RELAPSE FOLLOWING UPFRONT PLATINUM BASED CHEMOTHERAPY (2020) (0)
Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with retroperitoneal lymph node dissection and PNET specific chemotherapy. (2009) (0)
PD56-02 IS THE PERCENTAGE OF TERATOMA IN THE ORCHIECTOMY SPECIMEN PREDICTIVE OF TERATOMA IN THE RETROPERITONEUM AT THE TIME OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN MEN WITH NON-SEMINOMATOUS GERM CELL TUMORS? (2019) (0)
Postchemotherapy: Radical Retroperitoneal Lymph Node Dissection (1999) (0)
UROLOGY FOUNDED IN 1917 BY HUGH HAMPTON YOUNG (1989) (0)
Re: Editorial comment to monitoring of emission as direct intraoperative control for nerve sparing retroperitoneal lymphadenectomy. (1994) (0)
MP65-17 PROPOSED NODAL STAGING CLASSIFICATION IN UROTHELIAL CARCINOMA OF THE BLADDER BASED ON BURDEN OF LYMPH LODE INVOLVEMENT (2014) (0)
PD53-02 ONCOLOGIC EFFICACY OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR PATIENTS WITH PATHOLOGIC N1, N2, AND N3 DISEASE (2021) (0)
High intensity focused ultrasound (HIFU) treatment of BPH: results of a multi‐center phase III study (2003) (0)
1755 UROTHELIAL CARCINOMA WITH VARIANT HISTOLOGY: ANALYSIS OF DISTINCT PATTERNS OF INVASION (2013) (0)
PD51-02 ONCOLOGIC OUTCOMES OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR STAGE II SEMINOMA: INDIANA UNIVERSITY EXPERIENCE (2022) (0)
MP37-19 THE IMPACT OF BLEOMYCIN ON PULMONARY AND OPERATIVE MORBIDITY AFTER POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN GOOD RISK GERM CELL TUMORS (2018) (0)
707 CLINICAL AND PATHOLOGIC OUTCOMES OF TESTIS CANCER PATIENTS UNDERGOING REDO POST CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (2013) (0)
Long-term follow-up of chemotherapy-induced remissions in patients with disseminated nonseminomatous germ cell tumors. (2009) (0)
Prognostic and therapeutic significance of pelvic lymph node dissection (PLND) extent in high-grade localized prostate cancer (PCa) patients (pts) treated with prostatectomy. (2010) (0)
Handbook of Advanced Cancer Care: Urogenital complications (2003) (0)
MP56-02 EMPIRIC TREATMENT OF IDENTIFIED CLOSTRIDIUM DIFFICILE CARRIERS AT TIME OF CYSTECTOMY: PRELIMINARY OUTCOMES (2016) (0)
926: Impact of the Number of Positive Lymph Nodes on Disease Free Survival (DFS) for Patients with Pathologic Stage B1 Nonseminomatous Germ Cell Tumor (NSGCT) (2004) (0)
1176: Vascular Endothelial Growth Factor-C and Vascular Endothelial Growth Factor Receptor-3 as Predictors of Lymphatic Metastasis in Stage a Testis Cancer (2004) (0)
MP49-02 A STUDY TO EVALUATE THE PROGNOSTIC AND PREDICTIVE UTILITY OF CCP AND HRD ASSAYS AND GENETIC SEQUENCING IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER (2016) (0)
565 QUANTITATIVE ANALYSIS OF LYMPH NODE NUMBER RESECTED AT PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) (2010) (0)
664 OUTCOME OF VIABLE SEMINOMA AT POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (2012) (0)
Commentary (Foster): Prognostic Factors in Low-Stage Nonseminomatous Testicular Cancer (1996) (0)
An approach to the management of rare tumors. (2011) (0)
Survival of good-risk germ cell tumor patients following post-chemotherapy retroperitoneal lymph node dissection: The effect of bleomycin during induction chemotherapy. (2014) (0)
EDITORIAL COMMENT. (2019) (0)
Impact of the preparation technique on DNA content measured by image analysis in early stage human testis cancer (2007) (0)
Treatment of Multiply Recurrent Germ Cell Cancer (2003) (0)
[Role of primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous testicular tumors]. (1991) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard S. Foster?

Richard S. Foster is affiliated with the following schools:

Richard S. Foster's Academic­Influence.com Rankings

Why Is Richard S. Foster Influential?

Richard S. Foster's Published Works

Published Works

What Schools Are Affiliated With Richard S. Foster?

Richard S. Foster's AcademicInfluence.com Rankings